Prognosis of patients in end-stage heart failure with atrial fibrillation treated with ablation: Insights from CASTLE-HTx

The CASTLE-HTx trial demonstrated the benefit of atrial fibrillation (AF) ablation compared with medical therapy in decreasing mortality, need for left ventricular assist device implantation, or heart transplantation (HTx) in patients with end-stage heart failure (HF).

Source: Heart Rhythm - April 9, 2024 Category: Cardiology Authors: Maximilian Moersdorf, Jan G.P. Tijssen, Nassir F. Marrouche, Harry J.G.M. Crijns, Angelika Costard-Jaeckle, Leonard Bergau, Gerhard Hindricks, Nikolaos Dagres, Samuel Sossalla, Rene Schramm, Henrik Fox, Thomas Fink, Mustapha El Hamriti, Vanessa Sciacca, F Source Type: research